Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details) - Segments Information

v3.19.1
SEGMENT INFORMATION (Details) - Segments Information - USD ($)
 3 Months Ended
Jan. 31, 2019
Jan. 31, 2018
Oct. 31, 2018
Net loss:      
Net Loss $ (4,966,609) $ (1,865,474)  
Operating costs and expenses excluding non-cash share based compensation:      
Operating costs and expenses 2,233,564 1,607,613  
Plus non-cash share-based compensation 2,750,164 266,973  
Total operating costs and expenses 4,983,728 1,874,586  
Total assets:      
Total Assets 6,470,349   $ 6,448,542
Operating Segments [Member] | Cancer Detection Platform [Member]      
Net loss:      
Net Loss (1,804,354) (623,249)  
Operating costs and expenses excluding non-cash share based compensation:      
Operating costs and expenses 759,534 525,614  
Total assets:      
Total Assets 2,943,476   2,545,803
Operating Segments [Member] | CAR-T Therapeutics [Member]      
Net loss:      
Net Loss (2,487,285) (1,109,018)  
Operating costs and expenses excluding non-cash share based compensation:      
Operating costs and expenses 800,791 954,853  
Total assets:      
Total Assets 3,112,658   2,157,359
Operating Segments [Member] | Patent Licensing [Member]      
Net loss:      
Net Loss (674,970) (133,207)  
Operating costs and expenses excluding non-cash share based compensation:      
Operating costs and expenses 673,239 $ 127,146  
Total assets:      
Total Assets $ 414,215   $ 1,745,380